Arch raises $1.9B to build another crop of breakthrough biotechs

Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.

As with its earlier funds, Arch will use the money to place a wide range of bets, handing out $50,000 when appropriate but also dialing its investment up to $250 million to support grand plans such as its effort to transform biopharmaceutical manufacturing through Resilience.